Valuation : Obalon Therapeutics Inc

Market Cap 14.74M 12.68M 11.96M 10.9M 20.37M 1.41B 20.55M 142M 54.82M 715M 55.35M 54.14M 2.27B P/E 2026 *
-3.68x
P/E 2027 * -2.63x
Enterprise Value 14.74M 12.68M 11.96M 10.9M 20.37M 1.41B 20.55M 142M 54.82M 715M 55.35M 54.14M 2.27B EV / Sales 2026 *
111x
EV / Sales 2027 * 73.7x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 133K 115K 108K 98.56K 184K 12.75M 186K 1.29M 496K 6.47M 501K 490K 20.54M 200K 172K 162K 148K 276K 19.12M 279K 1.93M 744K 9.7M 751K 735K 30.81M
Net income -4M -3.44M -3.25M -2.96M -5.53M -382M -5.58M -38.66M -14.88M -194M -15.02M -14.69M -616M -7.85M -6.75M -6.37M -5.8M -10.84M -750M -10.94M -75.82M -29.18M -380M -29.46M -28.82M -1.21B
Net Debt - -
Logo Obalon Therapeutics Inc
Obalon Therapeutics, Inc. is a commercial-stage medical device company focused on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. The Company's product, Obalon balloon system, is a swallowable, gas-filled intragastric balloon designed to provide weight loss in obese patients. The Obalon balloon system is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed six months after the first balloon is placed. The Obalon balloon system intends to provide patients and physicians with a reversible and repeatable weight loss solution in an outpatient setting, without altering patient anatomy or requiring surgery. The Company has received Premarket approval (PMA) for its Obalon balloon system based on the results of its United States pivotal clinical trial, referred to as the SMART trial.
Employees
-
Sector
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!